Torsemide ER is under clinical development by Sarfez Pharmaceuticals and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Torsemide ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Torsemide ER overview
Torsemide (Soaanz) is a loop diuretic agent. It is formulated as tablets for oral route of administration. Soaanz is indicated in adults for the treatment of edema associated with heart failure or renal disease.
Torsemide ER is under development for the treatment of congestive heart failure. The therapeutic candidate is administered orally as an extended release tablet. The therapeutic candidate is an extended release loop diuretic and acts by targeting kidney-specific Na-K-Cl symporter. It was under development for the treatment of chronic kidney disease (CKD) and resistant hypertension.
Sarfez Pharmaceuticals overview
Sarfez Pharmaceuticals (Sarfez) is a pharmaceutical company that develops and distributes medical treatments. The company’s main product includes SOAANZ, a loop diuretic, which treats edema associated with heart failure or kidney disease. The product is designed for adult patients suffering from conditions such as heart failure, kidney disease and related symptoms. Its products under development pipeline products include SOAANZ, SZOO2 (MRA), SZOO3 Diuretic/SGL T2i, SZ004 SGL T2i/MRA, SZ005 Diuretic/MRA, SZ006 liquid diuretic, SZ007 Vasodilator. Sarfez is headquartered in Vienna, Virginia, the US.
For a complete picture of Torsemide ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
